Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

NCT04850157 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Interventions

DRUG: Tislelizumab
RADIATION: IMRT

Sponsor

Shanghai Zhongshan Hospital